Semax Peptide Research: UK Laboratory Guide | ADINA

Semax is a synthetic peptide that appears in a lot of research catalogues and a lot of consumer writing at the same time. For UK laboratory researchers and procurement teams, most of that consumer writing is noise. The questions that matter are narrower: what the molecule actually is, what the published literature has and has not examined, and what documentation accompanies the material you receive. This guide answers those questions in plain English, and it describes Semax strictly as a research-use-only material.

What Semax is

Semax is a synthetic heptapeptide analogue built on the ACTH(4-7) fragment of adrenocorticotropic hormone. The parent fragment is short – four residues – and the analogue extends it with a C-terminal Pro-Gly-Pro sequence, which is the part researchers most often single out when discussing its stability and behaviour in experimental systems.

The identification details most laboratories record on intake are:

• Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
• CAS number: 4037-01-8
• Molar mass: approximately 813.9 g/mol
• Molecular formula: C37H51N9O10S

These are identity facts, not efficacy claims. They are what lets you confirm that a stated material is the compound you asked for, and they belong on the batch record regardless of which catalogue term the supplier uses.

What the literature examines

The published work on Semax clusters around a few experimental themes. Most of it is preclinical – rodent and cell models rather than human studies – and it should be read as work on the compound in those systems, not as evidence about any particular supply.

Neurotrophic signalling. A recurring thread is the hippocampal BDNF/trkB system. Animal studies have reported changes in BDNF and trkB expression and activation after Semax administration, which researchers have used to argue that neurotrophic signalling is central to its observed effects.

Cerebral ischaemia models. Several rodent studies examine Semax in models of reduced cerebral blood flow, looking at neuroprotective and vascular endpoints alongside inflammatory markers such as VEGF. The proposed mechanisms involve both immune modulation and effects on the vascular system during ischaemia.

Immune and gene-expression work. A smaller group of studies examines how Semax alters expression of genes tied to immune-cell behaviour and immunoglobulin signalling, again largely in animal stroke models.

Behavioural models. Some work looks at exploratory activity, stress responses and learning in rodents. Findings here are model-specific and dose- and context-dependent, which is exactly the kind of detail that gets stripped out in consumer summaries.

Human and clinical literature. Semax has been studied clinically in a non-UK context, and it is described in that setting as a medicine. That literature is relevant background, but it does not transfer into a claim about unlicensed research material supplied in the UK.

Where the evidence ends

Two distinctions matter more than any single study.

The first is research on the compound versus the status of the material in front of you. A paper describing an effect of Semax in a rodent model tells you what happened in that model. It tells you nothing about the identity, documentation or handling of a specific vial. Those are separate questions with separate answers.

The second is preclinical versus human. Most of the mechanistic work is preclinical. Studies that describe human use come from a different regulatory and clinical context and do not make Semax a licensed medicine in the UK. Semax is not authorised for human or veterinary use here, and ADINA supplies it as research-use-only material for laboratory and analytical work. It is not intended for administration to humans or animals, and nothing in this article should be read as dosing, clinical or personal-use guidance.

Researchers should also treat mechanism as unsettled. The literature itself notes that the exact mechanisms of action are not fully clear, and proposed pathways – serotoninergic activation, BDNF regulation, immune crosstalk involving the Pro-Gly-Pro component – remain hypotheses under investigation rather than points of consensus.

How to assess a Semax research material

When a material arrives, what you can verify is concrete and worth checking deliberately:

1. Identity. Confirm the sequence, CAS number, molar mass and molecular formula against your own specification, and confirm they match across the label, the product page and any accompanying documents.
2. Documentation status. Ask what documentation exists for the batch and record its status honestly. Where a certificate of analysis or a supporting document is not yet available, it should be described as pending – not assumed, and not filled in from another supplier’s figures.
3. Batch traceability. Check that a batch or lot identifier on the vial ties back to the documents you were given, so a result can be linked to one physical material rather than a general product name.
4. Form and handling. Record the supplied form and follow the storage and handling instructions that accompany that material specifically.
5. Catalogue-term ambiguity. “Semax” is used loosely across catalogues. Confirm that the term you searched for maps to the specific analogue and specification you intend to work with.

None of these steps require a purity figure or a testing claim. They require a clear record of what is known, what is documented, and what is still pending.

How ADINA approaches Semax

ADINA supplies Semax as a research-use-only material for UK laboratories, research organisations and procurement teams. The listing is written for laboratory and analytical work: identification details, the supplied form, and a documentation status that is stated plainly, including anything still pending. We do not publish purity or testing figures we cannot substantiate, and we do not present human-use benefits, dosing or personal-use guidance for any catalogue material.

If you are sourcing Semax for a defined research purpose, start from the specification you need and the documentation you require, then confirm both against the material offered. That is a more reliable test of fit than any summary of the compound’s marketing history.

Frequently asked

Is Semax a licensed medicine in the UK? No. It is supplied by ADINA as research-use-only material, not as a medicine, and it is not authorised for human or veterinary use.

Can I rely on the published literature as a specification? No. The literature describes research findings in specific models. Your specification and the documentation for the actual batch are separate and should be checked independently.

Does ADINA state a purity figure? Only where it can be substantiated for the specific material. Where a supporting document is not yet available, its status is described as pending.

Which form does ADINA supply? Check the individual product page, which records the form, identification details and documentation status for that listing.

The takeaway

Semax is a well-defined molecule with a genuine preclinical research literature and an identity that is easy to verify. The useful work for a UK laboratory is to keep three things apart: what the compound is, what the research models have examined, and what the documentation says about the material you are holding. Treat each on its own terms, describe anything pending as pending, and you have a defensible basis for research use – which is the only basis ADINA supplies it for.